Human papillomavirus (HPV) type 16 and type 18 DNA loads at baseline and persistence of type- specific infection during a 2-year follow-up

Journal of Infectious Diseases

Volumn 200, Issue 11, 2009, Pages 1789-1797

  Xi, Long Fu ^a,c,e   Hughes, James P ^c   Edelstein, Zoe R ^c   Kiviat, Nancy B ^a   Koutsky, Laura A ^c   Mao, Constance ^b   Ho, Jesse ^a   Schiffman, Mark ^d  

^a School of Medicine   (United States)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Bldg B   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; SEROTYPE; VIRUS INFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LINEAR MODELS; LOGISTIC MODELS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 72849124070     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/647993     Document Type: Article

References (45)

1. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527 (Pubitemid 36159887) (Pubitemid 36159887)
2. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358:1782-1783
3. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180:1415-1423
4. Syrjänen S, Shabalova IP, Petrovichev N, et al. Clearance of high-risk human papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States of the former Soviet Union (the NIS cohort study). Eur J Obstet Gynecol Reprod Biol 2005; 119:219-227 (Pubitemid 40460386) (Pubitemid 40460386)
5. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66:10112-10119 (Pubitemid 44672065) (Pubitemid 44672065)
6. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87:1365-1371
7. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286:3106-3114 (Pubitemid 34016525) (Pubitemid 34016525)
8. Ylitalo N, Josefsson A, Melbye M, et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60:6027-6032 (Pubitemid 30839633) (Pubitemid 30839633)
9. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995; 61:306-311
10. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354:20-25 (Pubitemid 29304297) (Pubitemid 29304297)
11. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513-517
12. Lai CH, Chao A, Chang CJ, et al. Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 2008; 123:1685-1692
13. Fontaine J, Hankins C, Money D, et al. Human papillomavirus type 16 (HPV-16) viral load and persistence of HPV-16 infection in women infected or at risk for HIV. J Clin Virol 2008; 43:307-312 (Pubitemid 46052221) (Pubitemid 46052221)
14. Dalstein V, Riethmuller D, Prétet JL, et al. Persistence and load of highrisk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003; 106:396-403. (Pubitemid 36870403) (Pubitemid 36870403)
15. van Duin M, Snijders PJ, Schrijnemakers HF, et al. Human papillomavirus
16. load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002; 98:590-595
17. Park JY, Lee KH, Dong SM, Kang S, Park SY, Seo SS. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. Gynecol Oncol 2008; 108:549-554
18. Song SH, Lee JK, Oh MJ, et al. Persistent HPV infection after conization in patients with negative margins. Gynecol Oncol 2006; 101:418-422
19. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158:486-494 (Pubitemid 37022847) (Pubitemid 37022847)
20. Kulmala SM, Shabalova IP, Petrovitchev N, et al. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev 2007; 16:17-22. (Pubitemid 46174258) (Pubitemid 46174258)
21. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 2000; 44:726-742
22. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188:1383-1392
23. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-361
24. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36:3020-3027
25. Xi LF, Kiviat NB, Galloway DA, Zhou XH, Ho J, Koutsky LA. Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis 2008; 198:324-331
26. Xi LF, Koutsky LA, Castle PE, et al. Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst 2009; 101:153-161
27. Slinker BK, Glantz SA. Multiple linear regression is a useful alternative to traditional analyses of variance. Am J Physiol 1988; 255:R353-67.
28. Ylitalo N, Sørensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355:2194-2198 (Pubitemid 30394326) (Pubitemid 30394326)
29. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355:2189-2193 (Pubitemid 30394325) (Pubitemid 30394325)
30. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92:891-894 (Pubitemid 40462636) (Pubitemid 40462636)
31. Fen J, Yoshinouchi M, Nakamura K, et al. Eradication of HPV postsurgical treatments, its correlation with specific types, types of surgery and the physical status. Oncol Rep 2004; 12:375-379
32. Sarian LO, Derchain SF, Pittal Dda R, Andrade LA, Morais SS, Figueiredo PG. Human papillomavirus detection by hybrid capture II and residual or recurrent high-grade squamous cervical intraepithelial neoplasia after large loop excision of the transformation zone (LLETZ). Tumori 2005; 91:188-192
33. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682-690 (Pubitemid 32826418) (Pubitemid 32826418)
34. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337:1343-1349 (Pubitemid 27467768) (Pubitemid 27467768)
35. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190:37-45. (Pubitemid 38858402) (Pubitemid 38858402)
36. Rowhani-Rahbar A, Hawes SE, Sow PS, et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 2007; 196:887-894 (Pubitemid 47378939) (Pubitemid 47378939)
37. Vernon SD, Reeves WC, Clancy KA, et al. A longitudinal study of human papillomavirus DNA detection in human immunodeficiency virus type 1-seropositive and -seronegative women. J Infect Dis 1994; 169:1108-1112
38. Xi LF, Edelstein ZR, Meyers C, Ho J, Cherne SL, Schiffman M. Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species. Cancer Epidemiol Biomarkers Prev 2009; 18:2507-2512
39. Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002; 76:6480-6486 (Pubitemid 34633513) (Pubitemid 34633513)
40. McCarthy C, Youde SJ, Man S. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNAimmunisation ofHLA-A2/KBtransgenic mice. Int J Cancer 2006; 118:2514-2521
41. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183:8-15. (Pubitemid 32043036) (Pubitemid 32043036)
42. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-428 (Pubitemid 28135669) (Pubitemid 28135669)
43. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008; 197:1436-1447 (Pubitemid 351706468) (Pubitemid 351706468)
44. Pinto LA, Viscidi R, Harro CD, et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006; 353:451-462
45. Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2009; Jul 16 (Epub ahead of print).